- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Promedior Inaugurates New MA-based Lab and Office
Promedior Inc., a biotechnology company focused on developing biological theraepeutics to treat fibrotic diseases, announced that it has opened its new office and laboratory in Lexington, Massachusetts.
Promedior Inc., a biotechnology company focused on developing biological theraepeutics to treat fibrotic diseases, announced that it has opened its new office and laboratory in Lexington, Massachusetts.
As quoted in the press release:
Consolidating all of its operations, the new facility will serve as the company’s headquarters and completes the corporate move from the suburbs of Philadelphia, Pennsylvania. Promedior’s new facility includes state-of-the-art laboratories to support product development and commercialization of the company’s novel Pentraxin-2 therapeutics to treat fibrosis, including a number of rare diseases such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â